Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: Implications for gene therapy

Inflammatory Bowel Disease

(2010) Arthur Kaser et al.   Annual Review of Immunology

Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease

(2010) John J. Kim et al.   DIGESTIVE DISEASES AND SCIENCES

Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors

(2010) Sylvie Boutin et al.   HUMAN GENE THERAPY

Worldwide Epidemiology of Neutralizing Antibodies to Adeno‐Associated Viruses

(2009) Roberto Calcedo et al.   JOURNAL OF INFECTIOUS DISEASES

Inflammatory Bowel Disease and Mutations Affecting the Interleukin-10 Receptor

(2009) Erik-Oliver Glocker et al.   NEW ENGLAND JOURNAL OF MEDICINE

Current Directions in IBD Therapy: What Goals Are Feasible With Biological Modifiers?

(2008) William J. Sandborn   GASTROENTEROLOGY

Clinical gene therapy using recombinant adeno-associated virus vectors

(2008) C Mueller et al.   GENE THERAPY

Impact of Preexisting Vector Immunity on the Efficacy of Adeno-Associated Virus-Based HIV-1 Gag Vaccines

(2008) Jianping Lin et al.   HUMAN GENE THERAPY